top of page

News
March 2025
Synendos has been selected as a finalist of the Swiss Economic Award 2025
March 2025
Synendos has been selected for the Bio-Neuroscience Award for the "Best Pitch"
October 2024
Synendos Secures Innosuisse Funding to Advance Clinical Development of SYT-510
January 2024
Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510
July 2023
Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gordon Research Conference
bottom of page